FHHNC with ocular involvement is an autosomal recessive disorder with hypomagnesemia, hypercalciuria, nephrocalcinosis and coloboma often complicated by progressive chronic renal failure during childhood or adolescence. Loss of function mutations in the CLDN19 gene are the underlying genetic cause.
The first family as described by Michelis exhibited renal magnesium wasting and a distal renal tubular acidosis.[Error: Macro 'ref' doesn't exist]
The first typical symptom is nephrocalcinosis, which becomes apparent in childhood or adolescence. if not a sibling is affected or consanguinity present family history is not instructice as with all recessive disorders. Although the prevailing symptoms are renal and every so often end-stage renal failure develops, it is an multiorgan disorder. Ocular symptoms are pathognomonic of this disorder, and findings are myopia, nystagmus and chorioretinitis. Other organ's involvement includes tetany, seizures, hypertension, gout, deafness, chondrocalcinosis, and rickets.
Plasma magnesium is 0.59 ± 0.06 mmol/l. Renal magnesium excretion is inaprpriatly high 2.07 ± 0.073mmol/d. The same holds true for fractional magnesium excretion 12.5 ± 4.7%. Of note, trenal calcium excretion is also elevated. Urinary calcium creatinin ratio is 1.88 ± 0.67.
Often the patients present with urinary tract infections and carful sultrasound examination then reveals nephrocalcinosis. The diagnosis is further confirmed by laboratory findings and finally proved by molecular genetic tests of CLDN19.
It is only a symptomatic therapy available for this disorder, which includes substitution of renal mineral losses, the complex care for recurrent kidney stones, and antibiotics if urinary tract infections occur. Unfortunately these measures exert minimal effect on the progression of renal failure and ocular symptoms.
Hypomagnesemia is a cardinal symptom of FHHNC with ocular involvement. Typical of this disorder is further hypocalcemia, due to excessive renal losses of divalent cations; nephrocalcinosis; recurrent kidney stones; progressive renal failure; and macular coloboma.
Hypocalcemia is typical of FHHNC with ocular involvement though hypomagnesemia is essential. Other crucial symptoms are nephrocalcinosis, recurrent kidney stones, progressive renal failure, and macular coloboma.
Nephrocalcinosis in FHHNC with ocular involvement is accompanied by hypomagnesemia and hypocalemia due to excessive renal losses. By contrast to other diseases with nephrocalcinosis, progressive renal failure is typical. Also ocular invovment is essential for the diagnosis.
Hypercalciuria in FHHNC is accompanied by hypomagnesemia and nephrocalcinosis.
|Hereditary myokymia type 1|
|Hypomagnesemia with hypercalciuria and nephrocalcinosis|
|Hypomagnesemia with hypercalciuria and nephrocalcinosis with ocular involvement|
|Hypomagnesemia with normocalciuria|
|Intestinal hypomagnesemia with secondary hypocalcemia|
|Isolated dominant hypomagnesemia|
|Renal cysts and diabetes (RCAD)|
|Renal hypomagnesemia 6|
Bögler O et al. (1995) The p53 gene and its role in human brain tumors.
von Deimling A et al. (1995) Molecular pathways in the formation of gliomas.
Kimmelman AC et al. (1996) Loss of heterozygosity of chromosome 10p in human gliomas.
Chattopadhyay P et al. (1997) Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours.
Mollenhauer J et al. (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours.
Chernova OB et al. (1998) A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors.
Simons A et al. (1999) Isolation and characterization of glioblastoma-associated homozygously deleted DNA fragments from chromosomal region 9p21 suggests involvement of multiple tumour suppressor genes.